News - Starpharma

Latest News

Starpharma to present at US Drug Delivery Conference

Oct 8th, 2019

Starpharma today announced that it has been invited once more to present at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 7-8 October.

The PODD conference showcases the latest advances in drug delivery and provides networking opportunities with senior scientific and commercial executives from many of the major international pharmaceutical companies. This year’s PODD conference will be chaired by AstraZeneca’s Head of Drug Delivery, Dr Shawn Davis.

FDA Authorisation of First-in-Human Clinical Trial with AstraZeneca’s DEP® product AZD0466

Sep 26th, 2019

Starpharma today announced that that the U.S. Food and Drug Administration (FDA) has authorised the use of AstraZeneca’s DEP^® Bcl2/xL conjugate AZD0466 in clinical trials under an investigational new drug (IND) application. This is the first DEP^® candidate to reach this milestone from Starpharma’s multiproduct license with AstraZeneca.

$DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model$

DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model

Sep 12th, 2019

Starpharma today announced that its patented clinical stage nanoparticle formulation, DEP^® irinotecan, showed significantly enhanced efficacy benefits over standard irinotecan (Camptosar^®) and olaparib (Lynparza^®) alone and in combination, in an irinotecan-refractory HT-29 human colon cancer xenograft model.

VivaGel® BV regulatory approvals continue in Asia

Sep 3rd, 2019

Starpharma today announced that it has received a further regulatory approval in an Asian country for VivaGel^® BV. This approval follows multiple country approvals in the region as previously announced on 15 August 2019. Mundipharma will be rolling-out the product in Asia under the brand name BETADINE^TM BV Gel.

In the media

Starpharma’s VivaGel® BV regulatory approvals continue in Asia

Sep 3rd, 2019

Finance News Network reported Starpharma received further regulatory approval in another Asian country for its breakthrough product for bacterial vaginosis, VivaGel^® BV. The news follows the first approval in the region announced on 15 August.

Read the full news coverage here.

Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones

Aug 30th, 2019

Online news outlet Boardroom Media interviewed Starpharma CEO Dr Jackie Fairley following the release of its annual report and full-year results. In the interview, Dr Fairley shared the company’s latest DEP^® trial results, as well as VivaGel^® and upcoming milestones.

To listen to the full interview, click here.

Starpharma sees positive results in ovarian cancer treatment

Aug 29th, 2019

Online investor news outlet Finance News Network reported Starpharma’s positive results for its novel HER-2 targeted DEP^® conjugate (ADC) which outperformed the leading HER-2 ADC, Kadcyla^®, in a human ovarian cancer model.

To watch the full news video, click here.

Promising efficacy signals for Starpharma’s DEP® trials

Aug 28th, 2019

Biotech trade publication noted Starpharma announced promising efficacy signals in its ongoing clinical trials for both DEP^® cabazitaxel and DEP^® docetaxel.

To read the full article, click here.